HIA
BHVN

Harbor Investment Advisory’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Harbor Investment Advisory’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-10
Closed -$2K – 1408
2022
Q3 		$2K Sell
10
-50
-83% -$7.41K ﹤0.01% 1255
2022
Q2 		$9K Sell
60
-527
-90% -$67.3K ﹤0.01% 1050
2022
Q1 		$70K Hold
587
– – 0.01% 645
2021
Q4 		$81K Buy
587
+119
+25% +$15.1K 0.01% 597
2021
Q3 		$65K Buy
468
+111
+31% +$13.9K 0.01% 658
2021
Q2 		$35K Buy
357
+347
+3,470% +$28.2K ﹤0.01% 800
2021
Q1 		$1K Hold
10
– – ﹤0.01% 1245
2020
Q4 		$1K Buy
+10
New +$847 ﹤0.01% 1189
2020
Q3 		– Sell
-6
Closed – – 1299
2020
Q2 		$0 Buy
+6
New +$319 ﹤0.01% 1260

Other funds holding BHVN

LIP
Liontrust Investment Partners London, United Kingdom $5.86B AUM 23.75% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
MSCM
McElhenny Sheffield Capital Management Dallas, Texas $404M AUM 19.8% 1-Year Est. Return

Harbor Investment Advisory's BHVN Position: Q4 2022 in Review

Harbor Investment Advisory sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q4 2022, closing a stake of 10 shares — an estimated $2K sold.

Harbor Investment Advisory first reported a position in BHVN in Q2 2020 and held it in 9 quarters. The position peaked at $81K in Q4 2021. 7 funds tracked by Wall St. Rank hold BHVN as of Q4 2022.

  • Harbor Investment Advisory reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q4 2022 after selling out during the quarter.
  • Harbor Investment Advisory sold 10 Biohaven Pharmaceutical Holding Company Ltd. shares in Q4 2022, an estimated $2K.
  • Harbor Investment Advisory first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q2 2020 and held it in 9 quarters.
  • Harbor Investment Advisory's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $81K in Q4 2021.
  • 7 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q4 2022.

Based on Harbor Investment Advisory's 13F filing for Q4 2022, filed 24 Jan 2023.